Cohance Lifesciences peers

Companies like Cohance Lifescienceslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

COHANCE₹452.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹17,294 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
COHANCE
FY26
DIVISLAB
FY26
SYNGENE
FY26
ASTERDM
FY26
Peer
Average
Valuation — at last close
P/E96.38×92.20×◆ 46.61×86.32×75.04× +28%
P/B4.42×14.10×◆ 3.05×7.36×8.17× -46%
EV/EBITDA40.42×67.70×◆ 14.70×36.97×39.79× +2%
Market Cap₹17,294 Cr₹2.36L Cr₹14,780 Cr₹33,678 Cr₹94,946 Cr -82%
Growth
Revenue CAGR 3Y◆ 19.17%10.78%5.40%-26.99%-3.60% +632%
Revenue CAGR 5Y◆ 17.57%8.67%11.35%-11.61%2.80% +527%
Net Income CAGR 3Y-28.53%◆ 12.09%-11.98%-3.51%-1.13% -2417%
Revenue YoY (latest Q)-23.13%◆ 27.80%-8.55%21.60%13.62% -270%
Net Income YoY (latest Q)-197.39%◆ 65.50%-52.01%-68.70%-18.40% -973%
Profitability
EBITDA Margin18.82%◆ 32.59%24.57%19.41%25.52% -26%
Net Income Margin6.62%◆ 24.32%8.47%9.20%14.00% -53%
Return on Common Equity6.39%◆ 16.19%6.62%9.70%10.84% -41%
Return on Capital Employed6.18%◆ 17.80%8.54%9.90%12.08% -49%
Return on Assets3.43%◆ 13.89%4.57%5.80%8.09% -58%
Credit & Quality
Total Debt/Equity0.04×◆ 0.00×0.00×0.15×0.05× -20%
Interest Coverage6.44×◆ 129.48×9.54×5.18×48.07× -87%
Scale — latest FY
Revenue / Total Income₹2,269 Cr₹10,560 Cr₹3,739 Cr₹4,643 Cr₹6,314 Cr -64%
Net Income₹150 Cr₹2,568 Cr₹317 Cr₹427 Cr₹1,104 Cr -86%
Total Assets₹5,730 Cr₹20,033 Cr₹7,055 Cr₹8,112 Cr₹11,733 Cr -51%
EPS₹4.69₹96.75₹7.87₹7.53₹37.38 -87%
Book Value per Share₹102.23₹632.49₹120.11₹88.31₹280.3 -64%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.